Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Hoffmann-La Roche
University of Alabama at Birmingham
University of Washington
VA Office of Research and Development
Revolution Medicines, Inc.
Institut Bergonié
H. Lee Moffitt Cancer Center and Research Institute
Mereo BioPharma
VA Office of Research and Development
Sanofi